1. Short title This Act may be cited as the Protecting Medicare from Excessive Price Increases Act of 2018 . 2. Medicare part B rebate by manufacturers for certain drugs with prices increasing faster than inflation (a) In general Section 1834 of the Social Security Act ( 42 U.S.C. 1395m ) is amended by adding at the end the following new subsection: (w) No payment without rebate by manufacturers for single source drugs with prices increasing faster than inflation (1) No payment for noncompliant manufacturers Subject to the subsequent paragraphs of this subsection, no payment shall be available under this part for a unit of a rebatable drug of a manufacturer (as defined in section 1847A(c)(6)(A)) for each calendar quarter beginning on or after July 1, 2019, if such manufacturer has failed to comply with the requirement under paragraph (2)(B)(i) for the rebate period with respect to such calendar quarter. (2) Requirements (A) Secretarial provision of information Not later than 6 months after the end of each rebate period with respect to a calendar quarter beginning on or after July 1, 2019, the Secretary shall, for each rebatable drug, report to each manufacturer of such rebatable drug— (i) information on the total number of units described in subparagraph (A)(i) of paragraph (4) with respect to such drug and rebate period; (ii) information on the amount (if any) of the excess average sales price increase described in subparagraph (A)(ii) of such paragraph for such drug and period